CDK5 and breast cancer: Loss of Cdk5 has been demonstrated to act in breast cancer cells by increasing their sensitivity to drug therapy due to dysregulation of mPTP-dependent mitochondrial functions causing intrinsic apoptosis through increased ROS production and caspase activation [158].